Raptor Pharmaceutical announced that enrollment is complete in its Phase 2/3 clinical trial of Cysteamine Bitartrate Delayed-release Capsules for the potential treatment of Huntington's Disease. The 96-patient, Phase 2/3 clinical trial is being conducted under a collaboration agreement with The Centre Hospitalier Universitaire d'Angers, with 8 active clinical sites throughout France.
There’s just about no tolerance left in America for wealthy people griping about their financial woes. But is it …